Statistical Consideration and Challenges in Bridging Study of Personalized Medicine
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2014/06/04
-
Indian UGC (journal)
-
Refrences16
-
Citations17
-
Meijuan Li
Cite
Li, Meijuan. “Statistical Consideration and Challenges in Bridging Study of Personalized Medicine”. Journal of Biopharmaceutical Statistics, vol. 25, no. 3, 2014, pp. 397-0, https://doi.org/10.1080/10543406.2014.920340.
Li, M. (2014). Statistical Consideration and Challenges in Bridging Study of Personalized Medicine. Journal of Biopharmaceutical Statistics, 25(3), 397-407. https://doi.org/10.1080/10543406.2014.920340
Li M. Statistical Consideration and Challenges in Bridging Study of Personalized Medicine. Journal of Biopharmaceutical Statistics. 2014;25(3):397-40.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
Science
Mathematics
Probabilities
Mathematical statistics
You May Also Like
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies
- Sample size of 12 per group rule of thumb for a pilot study
- Guidelines for accurate EC50/IC50 estimation
- Quantifying heterogeneity in a meta‐analysis
- Multiple imputation using chained equations: Issues and guidance for practice
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| 10.1002/9781119013563 | 2002 | |||
| The Prevention and Treatment of Missing Data in Clinical Trials | 2010 | |||
| Asymptotic Confidence Intervals for Indirect Effects in Structural Equation Models | Sociological Methodology |
| 6,613 | 1982 |
| 10.1002/9780470316481 | ||||
| 10.7326/0003-4819-127-8_Part_2-199710151-00064 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic | The Journal of Molecular Diagnostics |
| 1 | 2024 |
| Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial | Journal of Thoracic Oncology |
| 2024 | |
| Statistical considerations for some issues in clinical bridging studies evaluating companion diagnostic devices | Journal of Biopharmaceutical Statistics |
| 2023 | |
| The impact of misclassification errors on the performance of biomarkers based on next-generation sequencing, a simulation study | Journal of Biopharmaceutical Statistics |
| 2023 | |
The Future of Precision Medicine in the Cure of Alzheimer’s Disease | Biomedicines |
| 10 | 2023 |
Citations Analysis
The category
Science: Mathematics: Probabilities. Mathematical statistics 8
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Statistical innovations in the medical device world sparked by the FDA and was published in 2015. The most recent citation comes from a 2024 study titled Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic. This article reached its peak citation in 2023, with 3 citations. It has been cited in 11 different journals, 18% of which are open access. Among related journals, the Journal of Biopharmaceutical Statistics cited this research the most, with 6 citations. The chart below illustrates the annual citation trends for this article.